A Phase 1, Two Parts, Open-label, Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt (EYP651) in Healthy Volunteers and Evaluation of Potential Drug-Drug Interactions
Latest Information Update: 10 Dec 2025
At a glance
- Drugs EYP 651 (Primary) ; Vonafexor (Primary)
- Indications Diabetic nephropathies; Hepatitis B; Hereditary nephritis; Kidney disorders; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors ENYO Pharma
Most Recent Events
- 26 Nov 2025 Status changed from not yet recruiting to recruiting.
- 13 Oct 2025 Status changed from planning to not yet recruiting.
- 19 Jun 2025 New trial record